ICRF and CRI co-fund grant to address immunotherapy resistance in melanoma led by Asaf Madi, PhD. – Tel Aviv University.
A recent study overseen by Dr. Asaf Madi from Tel Aviv University aims to enhance the effectiveness and longevity of TIL therapy for individuals facing advanced illnesses. In an announcement made on January 22, 2026, in New York, the Israel Cancer Research Fund (ICRF) and the Cancer Research Institute (CRI) disclosed their collaboration on a fresh award. This initiative seeks to boost the reliability and durability of TIL therapy for patients, highlighting the commitment to advancing cancer treatment options.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments